| Germline and somatic genetic landscape of pediatric myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Treatment of lower-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Treatment of high-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Diagnosis of myelodysplastic syndromes: the classic and the novel |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
|
Haematologica |
Aplastic Anemia |
| Diagnosis of myelodysplastic syndromes: the classic and the novel |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Genome sequencing in the management of myelodysplastic syndromes and related disorders |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Treatment of lower-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
